February 01, 2021 08:32 ET | Source: Vaxil Bio Ltd.
FURTHER UPDATE ON USAMRIID CHALLENGE AND ADDITIONAL EUROPEAN PATENT GRANTED FOR VAXILS ANTICANCER ANTIBODY PLATFORM
Not for distribution by US newswire or in United States
NESS-ZIONA, Israel, Feb. 01, 2021 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (Vaxil or the Company) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that Dr. Michael Berelowitz has been appointed as special advisor to its board.
Dr. Michael Berelowitz, formerly Pfizers Head of Clinical Development and Medical Affairs (Specialty Care), has enjoyed a 50+ year career in the biomedical sciences across the clinical practice of medicine, basic and clinical research and teaching, along with senior responsibilities in administration, budget management, and people leadership in academia and pharmaceutical companies/industry settings. Michael has also served on company boards, including public companies. This diverse experience provides Michael with a unique and valuable understanding of the world's biopharmaceuticals and their future. Dr. Berelowitzs full bio is detailed below.
Dr. Berelowitz has been granted 125,000 stock options (the "Options") pursuant to theCompany's stock option plan, exercisable into an equal amount ofcommon shares in the capital of the Company (Common Shares) at an exercise price of CAD$0.42 per Common Share. The Options vest in four equal installments, with the first installment on March 31, 2021, and the subsequent installments on June 30, 2021, September 30, 2021 and December 31, 2021 respectively. All the Options expire on February 1, 2026.
The company further updates that the USAMRIID experiment is proceeding on schedule, including the COVID-19 challenge, which was administered late last week.
The Company further advises that it has successfully obtained a European patent for its anticancer antibody platform - European Patent EP2756307B1 entitled Antibodies directed against signal peptides, methods and uses thereof. This granted patent provides broad patent protection for an antibody for use in the treatment of a MUC1 expressing cancer, as well as for an ex vivo method of diagnosing cancer in a subject and an ex vivo method for determining the suitability for treatment of a subject suffering from a MUC1 expressing cancer. Kits for practicing these methods are also included. This patent strengthens Vaxil Bios broad patent coverage with regards to its proprietary anti-cancer and anti-pathogenic portfolio.
We are very pleased to welcome Michael as a special advisor to our board. His extensive and relevant experience will significantly add to our talented team of executives and scientists. I am excited to be able to bring his medical background together with business acumen to support our portfolio and future growth as we progress through preclinical and future clinical phases, said David Goren, Vaxils Chairman and Chief Executive Officer, and continued, the granting of an additional European patent bolsters our already robust patent portfolio and demonstrates our commitment to further expand our pipeline across oncology and infectious diseases.
Full Bio for Dr. Michael Berelowitz.MB.ChB, FCP(SA), FACP, MBA
Dr. Berelowitz grew up and received his education in Zimbabwe and South Africa. He attended the University of Cape Town Medical School, graduating (MB.ChB) in 1968. He completed his internship, residency training in Internal Medicine (FCP(SA)), and fellowship training in Endocrinology and Metabolism at the affiliated Groote Schuur Hospital.
In 1977 Dr. Berelowitz moved to the United States to pursue a career in academic medicine - at the University of Chicago - Michael Reese Hospital (1977-1981), University of Cincinnati College of Medicine (1981-1985), and SUNY Stony Brook School of Medicine (1985-1996) as Professor of Medicine, Pharmacology and Biophysics where he led the Division of Endocrinology and Metabolism.
In 1996 Michael joined Pfizer Inc and over the next 15 years enjoyed positions of increasing responsibility leading the Diabetes unit, Cardiovascular group, Global Medical organization and finally serving as Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit (from 2009 - 2011).
Michael continues to be active in bringing his experiences to bear as a member of the Board of Directors of Recro Pharma and as Scientific Advisor to Kamada Ltd. and DIR Technologies. In 2020, he was elected to serve on the International Board of Directors of the Weizmann Institute.
Over the years, Michael has chaired the Task Force on Research of the New York State Council on Diabetes, served on the board of directors of the American Diabetes Association and the Clinical Initiatives Committee of the Endocrine Society, and on several editorial boards, includingThe Journal of Clinical EndocrinologyandMetabolism, Endocrinology,Reviews in Endocrine and Metabolic DisordersandClinical Diabetes.
Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes, and metabolic disorders.
ABOUT VAXIL
The company posts periodic updates through videos from the official companys youtube channel https://www.youtube.com/channel/UC0M029aN8g6beW09Drgt0dQ
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit, Vaxils proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by educating or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxils mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (seewww.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
CONTACT INFORMATION For further information please visithttp://vaxil-bio.com/or contact: North Equities, info@northequities.com David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000 Company Youtube channel
Go here to read the rest:
Vaxil Appoints a Special Advisor to the Board of Directors - GlobeNewswire
- Cardiology and Cardiac Pharmacology - April 4th, 2018 [April 4th, 2018]
- EMS Pharmacology: Drugs That Affect the Cardiovascular System ... - April 8th, 2018 [April 8th, 2018]
- EMS Pharmacology: Drugs That Affect the Cardiovascular ... - April 11th, 2018 [April 11th, 2018]
- Cardiology Conferences - Cardiology and Cardiovascular ... - June 5th, 2018 [June 5th, 2018]
- Cardiovascular Pharmacology: Open Access - Open Access ... - June 21st, 2018 [June 21st, 2018]
- CV Pharmacology | Welcome to Cardiovascular Pharmacology ... - July 31st, 2018 [July 31st, 2018]
- Cardiology Conferences | Cardiac pharmacology 2018 ... - September 13th, 2018 [September 13th, 2018]
- Cardiology Conference | Cardiac Pharmacology 2019 ... - November 18th, 2018 [November 18th, 2018]
- Cardiovascular Pharmacology Online Course | Lecturio - November 30th, 2018 [November 30th, 2018]
- Cardiovascular Pharmacology: Open Access - December 16th, 2018 [December 16th, 2018]
- Cardiovascular In vivo Models for Drug Discovery - December 21st, 2018 [December 21st, 2018]
- UTHSC College of Medicine: Department of Pharmacology - February 2nd, 2019 [February 2nd, 2019]
- Department of Pharmacology - School of Medicine - LSU ... - April 5th, 2019 [April 5th, 2019]
- Cardiovascular Pharmacology: Open Access - longdom.org - April 22nd, 2019 [April 22nd, 2019]
- ASPET | Cardiovascular Pharmacology - September 14th, 2019 [September 14th, 2019]
- Pharmacogenomics Market (PGx) Competitive Research And Precise Outlook 2019 To 2025: Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of... - September 18th, 2019 [September 18th, 2019]
- Global and Chinese Microbiome Drugs Market: Industry strategic plan for the period 2019-2024 - Market Report Gazette - September 18th, 2019 [September 18th, 2019]
- Pharmacokinetics Market To Increase at Steady Growth Rate - Commerce Gazette - September 18th, 2019 [September 18th, 2019]
- Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) - BioSpace - September 18th, 2019 [September 18th, 2019]
- Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019 - Yahoo Finance - September 18th, 2019 [September 18th, 2019]
- Cardiac fibrosis study identifies key proteins that translate into heart disease - BSA bureau - September 18th, 2019 [September 18th, 2019]
- Nitric Oxide: Worldwide Therapeutics & Markets to 2028 with Profiles on 35 Companies & 18 Collaborations Tabulated - Yahoo Finance - September 18th, 2019 [September 18th, 2019]
- Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23 Annual Scientific Meeting - Yahoo Finance - September 18th, 2019 [September 18th, 2019]
- Is it risky to continue with blood thinner drugs after a gastrointestinal bleed? - Medical News Bulletin - September 18th, 2019 [September 18th, 2019]
- Women urged to exercise and eat well due to cholesterol after menopause - Sydney Morning Herald - September 18th, 2019 [September 18th, 2019]
- Former Executive Director of Preclinical Safety at Novartis, Klaus Peter Hoffmann, MD, PhD, Joins NDA Partners as Expert - Yahoo Finance - September 18th, 2019 [September 18th, 2019]
- Yale alumna Dr. Nancy Brown named dean of Yale School of Medicine - Yale News - September 18th, 2019 [September 18th, 2019]
- Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer - Business Wire - October 7th, 2019 [October 7th, 2019]
- G-Protein Coupled Receptors (GPCRs) Market Size And Prediction By Leading Manufacturers According To Its Application And Types Till 2022 - Space... - October 7th, 2019 [October 7th, 2019]
- Best supplements for blood pressure: The natural remedy proven to lower your reading - Express - October 7th, 2019 [October 7th, 2019]
- Advanced Drug Delivery Systems Market Growth Analysis 2019 to Share Key Aspects of the Industry with the details of Influence Factors Forecast to 2024... - October 28th, 2019 [October 28th, 2019]
- The 9 Biggest Technology Trends That Will Transform Medicine And Healthcare In 2020 - Forbes - November 6th, 2019 [November 6th, 2019]
- Potential PF Therapy AD-214 to Move into Phase 1 Testing in Humans - Pulmonary Fibrosis News - November 6th, 2019 [November 6th, 2019]
- Edited Transcript of CYTK earnings conference call or presentation 31-Oct-19 8:30pm GMT - Yahoo Finance - November 6th, 2019 [November 6th, 2019]
- The Montreal Heart Institute celebrates its 500th heart transplant - GlobeNewswire - November 6th, 2019 [November 6th, 2019]
- Latest Research Report to uncover key Factors of Global Cardiovascular Repair And Reconstruction Devices Market - Market Research Base - November 6th, 2019 [November 6th, 2019]
- Global Cardiovascular Repair And Reconstruction Devices Market: Development History, Current Analysis and Estimated Forecast to 2025 - Market Research... - November 29th, 2019 [November 29th, 2019]
- The cardiac safety services market is projected to reach USD 752 million by 2024 from USD 442 million in 2019, at a CAGR of 11.2% - Yahoo Finance - December 11th, 2019 [December 11th, 2019]
- Evaluation of the Effect of Fish Oil Alone and in Combination with a P | DMSO - Dove Medical Press - January 13th, 2020 [January 13th, 2020]
- Amarin's Multiple Positives And Other News: The Good, Bad, And Ugly Of Biopharma - Seeking Alpha - January 25th, 2020 [January 25th, 2020]
- Heres What We Know About CBDs Effects On Varicose Veins - The Fresh Toast - January 28th, 2020 [January 28th, 2020]
- Hypertension: This Spice Can Help You Control High Blood Pressure Easily And Effectively - Doctor NDTV - January 28th, 2020 [January 28th, 2020]
- Cannabis Manual: Better Together - Weekly Alibi - January 30th, 2020 [January 30th, 2020]
- Pharmacology: Cardiovascular Drugs 1 (30 Items) - Nurseslabs - March 1st, 2020 [March 1st, 2020]
- A central master driver of psychosocial stress responses in the rat - Science Magazine - March 9th, 2020 [March 9th, 2020]
- The Global Cardiac Safety Services Market is expected to grow from USD 419.45 Million in 2018 to USD 865.23 Million by the end of 2025 at a Compound... - March 29th, 2020 [March 29th, 2020]
- Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment -... - March 29th, 2020 [March 29th, 2020]
- Fresh Produce In Short Supply? Prioritize This Veggie In Your Diet - mindbodygreen.com - April 25th, 2020 [April 25th, 2020]
- COVID-19: What's RNA research got to do with it? - University of Rochester - May 1st, 2020 [May 1st, 2020]
- What Happens When You Add Other Drugs To Your LSD Trip? - VICE - May 1st, 2020 [May 1st, 2020]
- Toward a Pharmacology of Resolution - Harvard Magazine - May 1st, 2020 [May 1st, 2020]
- GLYCOMIMETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - May 2nd, 2020 [May 2nd, 2020]
- This Simple Breathing Advice From A Nobel Prize Winner Can Turn The Tables On Stress During The Coronavirus Lockdown - Forbes - May 2nd, 2020 [May 2nd, 2020]
- National Nurses Week 2020: What Experiences Have Shaped Your Nursing Career? - HealthLeaders Media - May 2nd, 2020 [May 2nd, 2020]
- Research Paper Stresses Importance of Repurposing Drugs Against COVID-19 - BioSpace - May 13th, 2020 [May 13th, 2020]
- Repurposing existing drugs to treat coronavirus will likely be quicker than a vaccine, scientists claim - CNBC - May 13th, 2020 [May 13th, 2020]
- Alzheimer's and Cannabis - Greenway - Greenway - May 18th, 2020 [May 18th, 2020]
- Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day - Business Wire - June 2nd, 2020 [June 2nd, 2020]
- Healthy people shouldn't take daily aspirin to prevent heart disease, review finds - WDJT - June 6th, 2020 [June 6th, 2020]
- Study reveals how living close to roadways may impact the brain - Drew Reports News - June 18th, 2020 [June 18th, 2020]
- Disruptions in circadian rhythms not only cause sleep disorders, but could also put you at risk of these... - Firstpost - June 18th, 2020 [June 18th, 2020]
- NeonMind Files Patent Application for Therapeutic Use of DMT - Yahoo Finance - June 18th, 2020 [June 18th, 2020]
- Vitamin D What you need to know about the sunshine vitamin - Medical News Bulletin - July 9th, 2020 [July 9th, 2020]
- Idorsia announces positive results in the second Phase 3 study of daridorexant - GlobeNewswire - July 9th, 2020 [July 9th, 2020]
- ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse - PRNewswire - July 9th, 2020 [July 9th, 2020]
- Drug Discovery Outsourcing Market Highly Favorable with new Demand to the Growth Rate by 2027| Thermo Fisher Scientific, Merck KGaA, Albany Molecular... - August 21st, 2020 [August 21st, 2020]
- Bringing Peer Review To Early COVID-19 Research, More News - Bio-IT World - August 21st, 2020 [August 21st, 2020]
- Cardiac Safety Services Market Research Report by Type of Service, by Type, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 -... - August 21st, 2020 [August 21st, 2020]
- UCI study finds women with diabetes and high levels of coronary artery calcium at greater risk of death than men - Newswise - August 21st, 2020 [August 21st, 2020]
- Globa Advanced Drug Delivery Systems Market 2020 Research, Key Players, Industry Overview, Supply and Consumption Analysis 2024 - Bulletin Line - September 2nd, 2020 [September 2nd, 2020]
- Esperion Announces Two Data Presentations of NEXLETOL (bempedoic acid) Tablet at the ESC Congress 2020 - GlobeNewswire - September 2nd, 2020 [September 2nd, 2020]
- Women with diabetes and high levels of coronary artery calcium at greater risk of death than men - UCI News - September 2nd, 2020 [September 2nd, 2020]
- 15 Clever Ways to Use Leftover Red Wine - Yahoo Lifestyle - September 2nd, 2020 [September 2nd, 2020]
- UK Study Leads to Better Understanding of Blood Pressure Regulation, Atherosclerosis - UKNow - September 2nd, 2020 [September 2nd, 2020]
- Academic always top of the class for pay and conditions - Extra.ie - September 15th, 2020 [September 15th, 2020]
- Cardiac Safety Services Market Size Is Rising Tremendously Due To Increasing Need of Healthcare Services Centralization Till 2025 - TC BizNews - September 15th, 2020 [September 15th, 2020]
- 5 Benefits of Berberine, Including Why It's a Healthy Gut All-Star - msnNOW - September 15th, 2020 [September 15th, 2020]
- Advanced Drug Delivery Systems Market 2020 Report Covers Key Growth Factors, Global Trends, Opportunities by Regions, Industry Size and Share... - September 23rd, 2020 [September 23rd, 2020]
- Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small... - September 23rd, 2020 [September 23rd, 2020]
- MASSIVE GROWTH OF DRUG DISCOVERY SERVICES MARKET WILL RAISE USD 19.1 BILLION BY 2027, CAGR +13% FROM 2020 TO 2027 WITH TOP KEY PLAYERS LIKE THERMO... - September 29th, 2020 [September 29th, 2020]